Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer

September 28, 2022

https://www.globenewswire.com/news-release/2022/09/28/2524126/28235/en/Cornerstone-Pharmaceuticals-Initiates-Phase-1-Trial-of-CPI-613-devimistat-in-Combination-with-Chemoradiation-for-the-Treatment-of-Advanced-Pancreatic-Cancer.html

Cranbury, Sept. 28, 2022 (GLOBE NEWSWIRE) —

September 28, 2022 – Cornerstone Pharmaceuticals, Inc., a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the initiation of a Phase 1 clinical trial evaluating CPI-613® (devimistat) in combination with chemoradiation for the treatment of advanced pancreatic cancer. Devimistat is the company’s first-in-class lead compound designed to target enzymes that are involved in cancer cell energy metabolism found within the mitochondria of cancer cells.

Read more at globenewswire.com

Related news for (RFL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.